used in adults with hypoparathyroidism (postoperative or idiopathic), pseudohypoparathyreosis and other diseases and conditions requiring correction of calcium and phosphorus metabolism, including the muscle cramps, tetany, testosterone enanthate injection spazmofilii due to hypocalcemia.
- Hypersensitivity to the preparations of vitamin D.
- Hypervitaminosis D.
- Tetany, caused by hyperventilation (including in cases of poisoning with carbon dioxide);
- Organic heart disease in the stage of decompensation.
- Pregnancy and lactation.Cautions
During treatment dihydrotachysterol drugs and dietary supplements containing calcium, vitamin D and parathyroid hormone should be used with caution because of the risk of hypercalcemia. It should also monitor the application of antacid and laxatives containing magnesium.
During the course of treatment is necessary to control the content of calcium and phosphorus in the blood serum and urine at least once per month in the initial phase of treatment, and after the selection of the optimal dose and stabilization of the patient – not at least once every three months. Particular care should be monitored levels of calcium in patients with kidney disease and heart disease, as prolonged hypercalcemia may lead to further deterioration of the functional state of the organ.
The drug should be administered with caution to patients with renal stone disease.Dosing and Administration
The drug is administered orally after meals. Metered drops from an eye dropper or dropper-stopper. One drop of the preparation contains 0.03 mg ; 1 ml of the preparation in the average 33 drops. Dose set individually depending on the patient and the calcium and phosphorus in the blood.
The daily dose is 17 to 50 drops (0.5 to 1.5 mg). At 7-10 days of treatment with pronounced positive changes in the content of calcium and phosphorus in the serum move on to maintenance therapy for 17-50 drops (0.5-1.5 mg) per day, 1-3 times a week. The treatment is carried out for a long time (from 2-3 months up to a year or more) depending on the nature of the disease. When supplemental calcium supplementation is possible to use lower doses .Side effect
The therapy dihydrotachysterol may develop hypercalcemia, symptoms which may be weakness, fatigue, headache, insomnia, thirst, tachycardia, rarely – arrhythmias, pallor, lack of appetite, nausea, vomiting, diarrhea or constipation.
In applying the drug in high doses may develop biliary dyskinesia.
When these symptoms should immediately consult a doctor.
An overdose of the drug manifested testosterone enanthate injection by hypercalcemia. In the case of receiving an overdose of the drug overturned. Recommended abundant fluid intake, diet with the exception of calcium, mineral oil. Action can appear within a month after stopping.
Frequent and prolonged hypercalcemia can lead to a deterioration of renal function, initially manifested by polyuria (especially at night), great thirst and proteinuria. Further diffusion calcification may occur, most expressed in the kidneys, which can lead to nephrolithiasis and / or nephrocalcinosis and renal failure. Calcification can occur in blood vessels, heart, lung, skin. In rare cases, there are changes to the cornea, teeth. Available hypercalcemic crisis dehydration, stupor, coma and azotemia.
When hypercalcemic Stroke carried intravenous saline, possibly with the addition of loop diuretics (furosemide or ethacrynic acid). Other measures include hemodialysis, the introduction of citrate or corticosteroids.
Interaction with other drugs
when taken concomitantly with vitamin D, as well as drugs and food supplements containing calcium, may develop hypercalcemia.
When concomitantly with thiazide diuretics and rifampicin may cause hypercalcemia.
enhances the action of cardiac glycosides, and calcium antagonists. Together with the admission dihydrotachysterol cardiac glycosides or calcium channel blockers may reduce the dose of the latter.
Barbiturates (phenobarbital), antiepileptic drugs [phenytoin (phenytoin), carbamazepine (finlepsin), primidone (hexamidine)], anion exchange resins (cholestyramine, colestipol) and petroleum jelly weaken pharmacological effect.
If the intake carried out simultaneously treated with thyroxine, after its cancellation may develop testosterone enanthate injection hypercalcemia.
in orange glass bottles of 10, 15, 20 or 30 ml.
List B. In the dark place at a temperature from 0 to 15 ° C.
Keep out of reach of children.
2 years 6 months. Do not use beyond the expiration date printed on the package.
Conditions of supply of pharmacies
on medical prescription.